Are we there yet? 40 years of successes and challenges for children and adolescents living with HIV

Rachel C Vreeman1,2,§, Natella Y Rakhmanina3,4,5, Winstone M Nyandiko6,7, Thanyawee Puthanakit8,1p and Rami Kantor9

© Corresponding author: Rachel C. Vreeman, Arnhold Institute for Global Health, One Gustave Levy Place, Box 1199, New York, New York 10029, USA. Tel: 212-824-7950. (rachel.vreeman@mssm.edu)

Keywords: HIV; paediatrics; children; adolescents; antiretroviral therapy; resistance

Received 10 May 2021; Accepted 17 May 2021
Copyright © 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Forty years ago, the first adult HIV cases were published, with infant cases following within a year [1]. As a few of these then-babies approach their 40th birthdays, both their growth and science’s growth tell dramatic stories. Antiretroviral therapy (ART) transformed HIV from a deadly infection into a chronic disease. Just as miraculous, an AIDS-free generation became imaginable, using ART to prevent >95% of perinatal transmission. While these advances in HIV prevention and treatment deserve celebration, attention should be devoted to remaining hurdles – such as behavioural, social viral suppression and drug resistance challenges – that must still be overcome to ensure successful life-long outcomes for the global population of children and adolescents who have grown up with HIV (CAWH).

The global HIV impact for CAWH continues to be enormous: in 2020, 1.8 million children under 14 live with HIV, and every day 400 still acquire HIV and 270 die from it. Although ART access has expanded, only 53% of CAWH were receiving ART in 2019. Many countries do not screen mothers or infants for HIV, which leads to perinatal transmission, late childhood diagnosis, and deaths. Two million adolescents live with HIV globally, approximately 80% in sub-Saharan Africa, for whom HIV remains the top cause of death. Older adolescents (15 to 19 years) are the only age group in which HIV-related deaths are not decreasing. In the face of these young deaths, current care models clearly are not working; of adolescents 10 to 19 years with HIV, only 43% engage in care, 31% are retained in care and a dismal 30% are virally suppressed [2]. Added challenges of COVID-19 pandemic-related disruptions on HIV testing and care remain to be fully quantified and understood for CAWH.

Behavioural and social challenges evolve throughout growth and development, from infants who spit out poorly palatable liquid medications like lopinavir/ritonavir; to school-aged CAWH who question why they take medicines; to adolescents living in stigmatizing environments and struggling to establish autonomy and fit in. Such challenges, on top of the difficulty accepting an HIV diagnosis, impact ART adherence and clinic engagement, with risks for worsening morbidity and mortality. Both adherence support and psychosocial counselling are less accessible to families in low-and-middle-income-countries (LMIC) [3]. Parents and caregivers struggle with disclosure to their children, often waiting until adolescence to explain how and why they have HIV out of concerns for their reaction and fears that they may disclose the family HIV status to others. Disclosure delays can hurt adherence, as can wrestling with diagnosis acceptance and avoiding sensitive disclosures to friends and sexual partners [4]. CAWH may have behavioural and mental health challenges, associated with more risky sexual behaviours, substance use and non-adherence [5]. CAWH are also at substantial risk of stigma and its deleterious effects. Challenges can be distinct from adults, like bullying, discrimination at or exclusion from schools, growing up with caregivers’ fears of stigma, internalizing stigma, violence and prosecution tied to sexual/gender orientation [6], and exacerbations of poverty, malnutrition and inequitable healthcare access [7]. While CAWH-focused HIV services may offer individualized behavioural and social support, transitioning into adult care often negatively affects older youth as they “age out” of more child-friendly paediatric health systems into larger clinics that lack such support services. This transition period can be a time of increased risks of poor adherence and viral outcomes [8].

Multiple factors contribute to challenges with viral suppression in paediatric HIV care, and CAWH do not achieve similar suppression levels as adults [9]. First, overall global roll-out of routine viral load testing has been slow, complicated by reliance on plasma-based specimens, and, particularly for CAWH,
limitations such as phlebotomy expertise and insufficient evidence for optimal scheduling of routine monitoring. Second, the limited number of ART formulations appropriate for and available to children make regimen modifications difficult, especially in LMIC. Only a quarter of approved formulations have dosing guidelines and are approved for children <2 years old, and may still be unpalatable or complex to administer [10]. Third, CAWH are less likely to participate in new therapeutic clinical trials, and regulatory approvals and guidelines are typically slow to extend to paediatric populations. The amalgamation of limited VLS monitoring, fewer ART options and poor adherence support contributes to undetected treatment failures, delayed ART switches and drug resistance accumulation [11].

Evaluating drug resistance across the lifespans of CAWH is, therefore, a particular concern. However, resistance testing as part of clinical care remains limited in LMIC, and its true burden is largely unknown [12]. The few available studies demonstrate extensive resistance to ART regimens commonly used in CAWH, whereas longitudinal outcomes data are limited to non-existent [13,14]. Even as newer medications with high barriers to resistance are rolled out for CAWH (e.g. second-generation integrase strand transfer inhibitors), scale-up challenges in the context of implementation, prior relevant ART exposures, and limited availability of formulations may still negatively affect the trajectory and impact of resistance [15]. Large unknown aspects of resistance (e.g. archived mutations, minority resistance variants, co-occurrence of mutations within genomes, alternative resistance mechanisms) may accompany CAWH into adulthood and become difficult to overcome in the future.

An AIDS-free generation should be possible, but we are not there yet. HIV remains a burden, not only in LMIC, but also in resource-rich settings like the United States, where systemic impacts of racism on healthcare access, poverty, incarceration, stigma, mental health, and substance use are exacerbated by disparities in perinatal and adolescent HIV transmission and treatment outcomes. As we honour our gains in HIV care delivery over the past 40 years, we must address the specific, nuanced and long-term challenges of living with HIV for CAWH, and realize that they cannot be treated as “typical adults with HIV” as they mature and grow older. Until we transform care systems, treatment regimens, adherence and mental health support, viral and drug resistance monitoring and global policy, this generation will remain vulnerable to high HIV transmission, morbidity and mortality. Setting priorities to support CAWH requires greater attention to the long-term implications of the unique challenges they have faced over the first decades of the HIV pandemic so that they can successfully reach the next chapters of their lives.

AUTHORS’ AFFILIATIONS

1Department of Global Health and Health System Design, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Arnold Institute for Global Health, New York, NY, USA; 3Division of Infectious Diseases, Children’s National Hospital, Washington, DC, USA; 4Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA; 5Technical Strategies and Innovation, Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA; 6Department of Child Health and Paediatrics, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya; 7Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya; 8Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 9Division of Infectious Diseases, Alpert Medical School, Brown University, Providence, RI, USA

COMPETING INTERESTS

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

AUTHORS’ CONTRIBUTIONS

All five authors (RV, NR, WN, TP and RK) meet the criteria for authorship and have made substantial contributions to various facets of the manuscript. This manuscript was initially conceptualized and written by RV and RK. All authors reviewed, edited and contributed significantly to writing subsequent versions of the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGEMENTS

We acknowledge the incredible privilege of caring for families living with HIV, and we are thankful for the tremendous contributions of our patients, clinical colleagues, community members, activists and researchers. We appreciate the daily gift of being guided by both data and insights from children, adolescents and young adults living with HIV.

FUNDING

This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health with support to RV and RK through NIH R01 AI147333 and R01 AI120792, with RK’s effort also supported through NIH K24 AI134359 and P30 AI042853 awards. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

REFERENCES

1. Centers for Disease Control (CDC). Unexplained immunodeficiency and opportunistic infections in infants – New York, New Jersey, California. MMWR Morb Mortal Wkly Rep. 1982;31(49):665-7.
2. Iyun V, Technau K-G, Vinikoor M, Yotebieng M, Vreeman R, Abuogi L, et al. Variations in the characteristics and outcomes of children living with HIV following universal ART in sub-Saharan Africa (2006–17): a retrospective cohort study. Lancet HIV. 2021;2:352-3018(21):4-7.
3. Ökonji EF, Mukumbang FC, Orth Z, Vickerman-Delport SA, Van Wyk B. Psychosocial support interventions for improved adherence and retention in ART care for young people living with HIV (10–24 years): a scoping review. BMC Public Health. 2020;20(1):1841.
4. Sirikum C, Sophonphan J, Chuangsuen T, Lakonphon S, Srimuan A, Chusut P, et al. HIV disclosure and its effect on treatment outcomes in perinatal HIV-infected Thai children. AIDS Care. 2014;26(9):1144–9.
5. Vreeman RC, McCoy BM, Lee S. Mental health challenges among adolescents living with HIV. J Int AIDS Soc. 2017;20:21497.
6. Kacarek D, Malek K, Mellsis CA, Tasiopoulos K, Smith R, Grant M, et al. Exposure to violence and virologic and immunological outcomes among youth with perinatal HIV in the pediatric HIV/AIDS cohort study. J Adolesc Health. 2016;59(1):30–7.
7. Vreeman RC, Scanlon ML, Tu W, Slaven J, McAteer C, Aluoch J, et al. Valida- tion of an HIV/AIDS stigma measure for children living with HIV and their fami- lies. J Int Assoc Provid AIDS Care. 2019;18:2325958219880570.
8. Ritchwood TD, Malo V, Jones C, Metzger IW, Atujuna M, Marcus R, et al. Healthcare retention and clinical outcomes among adolescents living with HIV after transition from pediatric to adult care: a systematic review. BMC Public Health. 2020;20(1):1195.
9. Boerma RS, Boender TS, Bussink AP, Calis JC, Bertagnolio S, Rinkes de Wit TF, et al. Suboptimal viral suppression rates among HIV-infected children in low- and middle-income countries: a meta-analysis. Clin Infect Dis. 2016;63(12):1645–54.
10. Penazzato M, Granahanmugan D, Rojo P, Lalleman M, Lewis LL, Rocchi F, et al. Optimizing research to speed up availability of pediatric antiretroviral drugs and formulations. Clin Infect Dis. 2017;64(11):1597–603.
11. Collaborative Initiative for Paediatric HIV Education and Research (CI-PhER) Global Cohort Collaboration. Outcomes of second-line antiretroviral
therapy among children living with HIV: a global cohort analysis. J Int AIDS Soc. 2020;23:e25477.
12. Inzaule SC, Oondo P, Peter T, Muyenyi PN, Stevens WS, de Wit TFR, et al. Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa. Lancet Infect Dis. 2016;16(11):e267–75.
13. World Health Organization. Global action plan on HIV drug resistance 2017–2021. 2017. [cited 2021 May 5]. Available at: https://www.who.int/hiv/pub/drugresistance/hivdr-action-plan-2017-2021/en/
14. Koay WLA, Kose-Otieno J, Rakhmanina N. HIV drug resistance in children and adolescents: always a challenge? Curr Epidemiol Rep. 2021;1–11.
15. Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, et al. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. BMC Infect Dis. 2021;21(1):5.